U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Go back to U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility| Astellas Pharma Inc Unsponsored ADR (AMEX: ALPMY) | Delayed: 13.42 +0.16 (1.21%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $13.26 | 52 Week High | $19.40 | |||
| Open | $13.34 | 52 Week Low | $12.50 | |||
| Day High | $13.44 | P/E | N/A | |||
| Day Low | $13.30 | EPS | $0.00 | |||
| Volume | 164,997 | |||||
| Pfizer Inc. (NYSE: PFE) | Delayed: 26.21 +0.04 (0.15%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $26.17 | 52 Week High | $37.39 | |||
| Open | $26.29 | 52 Week Low | $28.25 | |||
| Day High | $26.49 | P/E | 15.88 | |||
| Day Low | $26.11 | EPS | $1.65 | |||
| Volume | 38,768,485 | |||||
